Jakarta –
Vaccine manufacturer from the United States (US) Pfizer announced its revenue from sales of COVID-19 vaccines on Wednesday, (28/7/2021). Quoted from CNBC, in the second quarter of 2021, Pfizer’s COVID-19 vaccine managed to sell US$ 7.8 billion or around Rp 113 trillion (USD 14,497) due to high demand from many countries along with the delta variant spreading.
This revenue automatically increases the estimated sales in 2021 for vaccines to US$ 33 billion, equivalent to Rp 478 trillion from the previous US$ 26 billion Rp 375 trillion.
The second-quarter results also beat Wall Street’s expectations. The company currently expects annual revenue in the range of US$ 3.95 to US$ 4.05 per share, up from the previous range of US$ 3.55 to US$ 3.65 per share.
The company also expects revenue to be in the $78 billion to $80 billion range, up from its previous estimate of $70.5 billion to $72.5 billion. Currently Pfizer’s stock position is down 0.4% on the stock market.
“The second quarter was extraordinary in several ways. Most notably, the speed and efficiency of our efforts with BioNTech to help vaccinate the world against COVID-19 is unprecedented, with now over one billion doses of BNT162b2 shipped globally,” said the CEO. Pfizer Albert Bourla in a statement, quoted by CNBC.
Other Pfizer business units also experienced strong sales growth. Revenue from its oncology unit rose 19% year over year to US$ 3.1 billion, equivalent to Rp 44 trillion. Then the company’s hospital unit generated revenues of US$ 2.2 billion, equivalent to Rp. 33 trillion, up 21 percent from the previous year, and the internal medicine unit grew by 5 percent from last year to US$ 2.4 billion, equivalent to Rp. 34 trillion.
Pfizer said earlier this month they were seeing signs of diminishing immunity to German-produced COVID-19 vaccine BioNTech. It plans to ask the ‘Food and Drug Administration’ to authorize the booster dose.
He also said he was developing a booster vaccine to target the delta variant. In a slide posted Wednesday alongside its earnings report, Pfizer could potentially file an emergency use authorization for booster doses with the FDA in early August.
It hopes to start clinical studies to test the delta variant vaccine soon in the same month. He also expects full approval for his two-dose vaccine by January 2022.
(hns / hns)
– .
